Key Highlights: Implications: Relopduo gives BMS a next‑generation immunotherapy in India’s melanoma market, combining PD‑1 and LAG‑3 blockade to offer materially better pro...
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
